MUC1 and pancreatic neoplasm: In a phase I/II study (125) that included 48 patients with pancreatic cancer, outcomes were predicted based on baseline immunity; the patients received Wilms tumor 1 and/or MUC-1 peptide-loaded DC vaccination and standard chemotherapy.